References
- Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12:767–778.
- Elkayam U. Peripartum cardiomyopathy for the clinician: the known and the unknown. Eur J Heart Fail. 2017;19:1142–1144.
- Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation 2005;111:2050–2055.
- Patel PA, Roy A, Javid R, et al. A contemporary review of peripartum cardiomyopathy. Clin Med. 2017;17:316–321.
- Barasa A, Goloskokova V, Ladfors L, et al. Symptomatic recovery and pharmacological management in a clinical cohort with peripartum cardiomyopathy. J Matern Fetal Neonatal Med. 2018;31:1342–1349.
- Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000;283:1183–1188.
- Biteker M, Biteker G, Altun I, et al. Late recovery in peripartum cardiomyopathy. Int J Cardiol. 2015;187:316.
- Biteker M, Ilhan E, Biteker G, et al. Delayed recovery in peripartum cardiomyopathy: an indication for long-term follow-up and sustained therapy. Eur J Heart Fail. 2012;14:895–901.
- Biteker M. Current therapeutic perspectives in peripartum cardiomyopathy. Ann Thorac Surg. 2011;91:331. author reply 331–331; author reply 332.
- Mallick A, Januzzi JL. Jr., Biomarkers in acute heart failure. Rev Esp Cardiol (Engl Ed). 2015;68:514–525.
- Alonso-Martínez JL, Llorente-Diez B, Echegaray-Agara M, et al. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail. 2002;4:331–336.
- Gottdiener JS, Bednarz J, Devereux R, et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr. 2004;17:1086–1119.
- Fett JD, Sannon H, Thélisma E, et al. Recovery from severe heart failure following peripartum cardiomyopathy. Int J Gynecol Obstet. 2009;104:125–127.
- Modi KA, Illum S, Jariatul K, et al. Poor outcome of indigent patients with peripartum cardiomyopathy in the United States. Am J Obstet Gynecol. 2009;201:171.e1–171.e5.
- Goland S, Modi K, Bitar F, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail. 2009;15:645–650.
- Biteker M, Duran NE, Kaya H, et al. Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial. Clin Res Cardiol. 2011;100:571–577.
- Duran N, Günes H, Duran I, et al. Predictors of prognosis in patients with peripartum cardiomyopathy. Int J Gynecol Obstet. 2008;101:137–140.
- Hu CL, Li YB, Zou YG, et al. Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy. Heart. 2007;93:488–490.
- Fett JD, Dowell DL, Carraway RD, et al. One hundred cases of peripartum cardiomyopathy … and counting: what is going on?. Int J Cardiol. 2004;97:571–573.
- Forster O, Hilfiker-Kleiner D, Ansari AA, et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2008;10:861–868.
- Sarojini A, Sai Ravi Shanker A, Anitha M. Inflammatory markers-serumlevel of C-reactive protein, tumor necrotic factor-α, and interleukin-6 as predictors of outcome for peripartum cardiomyopathy. J Obstet Gynecol India. 2013;63:234–239.
- Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010;121:1465–1473.
- Hilfiker-Kleiner D, Haghikia A, Berliner D, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J. 2017;38:2671–2679.